The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-alcoholic Fatty Liver Disease: a Randomized, Double-blinded, Placebo-controlled, Clinical Trial

Overview

Journal J Health Popul Nutr

Publisher Biomed Central

Specialties Nutritional Sciences
Public Health

Date 2025 Mar 2

PMID 40025618

Authors

Mohammad Ali Mohsenpoor

Karim Parastouei

Maryam Taghdir

Marzieh Akbarzadeh

Sepideh Abbaszadeh

Mohammad Ali Abyazi Heris

Mohammad Reza Mansouri Rad

Mohammad Amin Jafari

Ronak Borzooei

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a disease with high complications. An increment in dietary fiber consumption is an approach to NAFLD management, and chitosan as dietary fiber can play a role in the management of NAFLD. Thus, the present study aimed to investigate the effect of chitosan supplementation on liver function, hepatic steatosis predictors, and metabolic indices in adults with NAFLD.

Methods: Seventy-two adults with NAFLD were randomly assigned to consume either 1.5 g/day chitosan or placebo along with a low-calorie (- 500 kcal/day) diet for 8 weeks in a parallel, randomized, double-blinded, placebo-controlled, clinical trial. Participants were assessed for dietary intake, physical activity, and anthropometric indices. Blood samples were taken to measure fasting blood sugar (FBS), cholesterol, triglycerides, high- and low-density lipoprotein (HDL and LDL). Liver function indices including alanine aminotransferase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT) were evaluated using blood samples as the primary outcomes. Fatty liver index (FLI), hepatic steatosis index (HSI), and triglyceride-glucose index (TyG) were calculated as hepatic steatosis predictors' indices.

Results: After 8 weeks of study, 66 participants finished the study. In comparison with placebo, chitosan supplementation reduced weight (P = 0.041), waist circumference (P = 0.049), AST (P = 0.040), ALT (P = 0.001), and GGT (P = 0.028). Although the reduction of FBS, triglycerides, cholesterol, LDL, FLI, HSI, and TyG, and increment in HDL was higher in the chitosan group, the results were not significant (P > 0.05).

Conclusions: Eight-week supplementation with 1.5 g/day chitosan along with a low-calorie diet could possibly reduce weight, waist circumference, AST, ALT, and GGT, and ameliorate NAFLD. Further investigations are recommended. Trial registration The trial was registered at IRCT.ir as IRCT20140502017522N4 (March 2023).

References

Guo W, Yi L, Zhou B, Li M . Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis. Nutr J. 2020; 19(1):130. PMC: 7709411. DOI: 10.1186/s12937-020-00647-4. View

Arslanow A, Teutsch M, Walle H, Grunhage F, Lammert F, Stokes C . Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. Clin Transl Gastroenterol. 2016; 7(6):e176. PMC: 4931593. DOI: 10.1038/ctg.2016.28. View

Moraru C, Mincea M, Frandes M, Timar B, Ostafe V . A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure. Medicina (Kaunas). 2018; 54(6). PMC: 6306953. DOI: 10.3390/medicina54060109. View

Qian M, Lyu Q, Liu Y, Hu H, Wang S, Pan C . Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar Drugs. 2019; 17(7). PMC: 6669476. DOI: 10.3390/md17070391. View

Can A, Uysal C, Palaoglu K . Short term effects of a low-carbohydrate diet in overweight and obese subjects with low HDL-C levels. BMC Endocr Disord. 2010; 10:18. PMC: 2994852. DOI: 10.1186/1472-6823-10-18. View

Mohsenpour M, Samadani M, Shahsavani Z, Golmakani M, Pishdad G, Ekramzadeh M . The effect of celery () powder on cardiometabolic factors in overweight/obese individuals with type 2 diabetes mellitus: A pilot randomized, double-blinded, placebo-controlled clinical trial. Food Sci Nutr. 2023; 11(9):5351-5363. PMC: 10494649. DOI: 10.1002/fsn3.3493. View

Fatahi S, Sayyari A, Salehi M, Safa M, Sohouli M, Shidfar F . The effects of chitosan supplementation on anthropometric indicators of obesity, lipid and glycemic profiles, and appetite-regulated hormones in adolescents with overweight or obesity: a randomized, double-blind clinical trial. BMC Pediatr. 2022; 22(1):527. PMC: 9442917. DOI: 10.1186/s12887-022-03590-x. View

Zhang J, Feng J, Bai Y, Che Q, Cao H, Guo J . Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice. Food Funct. 2023; 14(23):10459-10474. DOI: 10.1039/d3fo03745b. View

Lee P, Macfarlane D, Lam T, Stewart S . Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011; 8:115. PMC: 3214824. DOI: 10.1186/1479-5868-8-115. View

10.

Deuchi K, KANAUCHI O, Imasato Y, Kobayashi E . Effect of the viscosity or deacetylation degree of chitosan on fecal fat excreted from rats fed on a high-fat diet. Biosci Biotechnol Biochem. 1995; 59(5):781-5. DOI: 10.1271/bbb.59.781. View

11.

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W . Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22(1):63. PMC: 8919523. DOI: 10.1186/s12902-022-00980-1. View

12.

Mundi M, Velapati S, Patel J, Kellogg T, Abu Dayyeh B, Hurt R . Evolution of NAFLD and Its Management. Nutr Clin Pract. 2019; 35(1):72-84. DOI: 10.1002/ncp.10449. View

13.

Kim M, Lo C, Corey K, Luo X, Long L, Zhang X . Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. Clin Nutr. 2022; 41(2):356-364. PMC: 8815093. DOI: 10.1016/j.clnu.2021.12.014. View

14.

Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M . NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2020; 110(7):921-937. PMC: 8238775. DOI: 10.1007/s00392-020-01709-7. View

15.

Landberg R . Does Whole-Grain Intake Matter for the Risk of Developing Nonalcoholic Fatty Liver Disease?. J Nutr. 2022; 152(4):924-925. DOI: 10.1093/jn/nxac009. View

16.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

17.

Dawoud S, Al-Akra T, Zedan A . Hepatoprotective Effects of Chitosan and Chitosan Nanoparticles against Biochemical, Genetic, and Histological Disorders Induced by the Toxicity of Emamectin Benzoate. Rep Biochem Mol Biol. 2022; 10(3):506-514. PMC: 8718774. DOI: 10.52547/rbmb.10.3.506. View

18.

Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J . The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16(1):15. PMC: 5248473. DOI: 10.1186/s12944-017-0409-6. View

19.

Dorairaj V, Sulaiman S, Abu N, Abdul Murad N . Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines. 2022; 10(1). PMC: 8773432. DOI: 10.3390/biomedicines10010015. View

20.

Zhang J, Liu J, Li L, Xia W . Dietary chitosan improves hypercholesterolemia in rats fed high-fat diets. Nutr Res. 2008; 28(6):383-90. DOI: 10.1016/j.nutres.2007.12.013. View